LONDONBritain's AstraZeneca Plc (AZN.L) said on Friday it had agreed to buy ZS Pharma (ZSPH.O), paying a total $2.7 billion for its proprietary technology to develop novel treatments for hyperkalaemia, or high potassium levels.
AstraZeneca said it had agreed to pay $90 a share for the San Mateo, California-based firm.
21:06 Apple's Q4 2016 results: Better than expected with 45.5 million iPhones sold, but revenue continues to slide16
12:23 Lockheed Martin's quarterly profit handily beats estimates20
11:46 GM reports record 3Q earnings despite slowing US sales11
11:07 Procter & Gamble earnings: $1.03 a share, vs 98 cents expected17